PriceTargets.com logo

NASDAQ:CMPI - Checkmate Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: -23.81 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.50 As of 05/31/2022 01:00 AM ET
+0 (0.00%)
Get New Checkmate Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMPI

Analyst Price Target is $8.00
▼ -23.81% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Checkmate Pharmaceuticals in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a -23.81% upside from the last price of $10.50.

This chart shows the closing price for CMPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Checkmate Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2022BTIG ResearchDowngradeBuy ➝ NeutralLow
3/30/2022BTIG ResearchLower Price TargetBuy$29.00 ➝ $9.00Medium
10/17/2021BTIG ResearchInitiated CoverageBuy$29.00High
10/6/2021Bank of AmericaUpgradeNeutral ➝ Buy$7.00High
3/19/2021Jefferies Financial GroupLower Price TargetBuy$23.00 ➝ $19.00High
9/1/2020Jefferies Financial GroupInitiated CoverageBuy$22.00High
9/1/2020Bank of AmericaInitiated CoverageNeutral$19.00High
9/1/2020BMO Capital MarketsInitiated CoverageOutperform$32.00N/A
9/1/2020BTIG ResearchInitiated CoverageBuy$29.00N/A
(Data available from 8/12/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/15/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/14/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Checkmate Pharmaceuticals logo
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.50
Low: $10.50
High: $10.50

50 Day Range

MA: $10.46
Low: $10.37
High: $10.50

52 Week Range

Now: $10.50
Low: $2.00
High: $10.50

Volume

N/A

Average Volume

142,261 shs

Market Capitalization

$231.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Checkmate Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Checkmate Pharmaceuticals in the last twelve months: Bank of America Co., and BTIG Research.
View the latest analyst ratings for CMPI.

What is the current price target for Checkmate Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Checkmate Pharmaceuticals in the last year. Their average twelve-month price target is $8.00, suggesting a possible downside of 23.8%. BTIG Research has the highest price target set, predicting CMPI will reach $9.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $7.00 for Checkmate Pharmaceuticals in the next year.
View the latest price targets for CMPI.

What is the current consensus analyst rating for Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMPI will outperform the market and that investors should add to their positions of Checkmate Pharmaceuticals.
View the latest ratings for CMPI.

What other companies compete with Checkmate Pharmaceuticals?

Other companies that are similar to Checkmate Pharmaceuticals include Genfit, Omega Therapeutics, Poseida Therapeutics, Tenaya Therapeutics and Social Capital Suvretta Holdings Corp. III. Learn More about companies similar to Checkmate Pharmaceuticals.

How do I contact Checkmate Pharmaceuticals' investor relations team?

Checkmate Pharmaceuticals' physical mailing address is 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142. The company's listed phone number is 617-682-3625 and its investor relations email address is [email protected] The official website for Checkmate Pharmaceuticals is www.checkmatepharma.com. Learn More about contacing Checkmate Pharmaceuticals investor relations.